Abstract Number: 392 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Cardiovascular Risk Factors and Cardiovascular Disease In Rheumatoid Arthritis Patients Across International Regions: A Comparison Of The Corrona International and Corrona United States Registries
Background/Purpose: Cardiovascular disease (CVD) is a major comorbidity in patients (pts) with rheumatoid arthritis (RA). We explored variations in the prevalence of cardiovascular (CV) risk…Abstract Number: 290 • 2013 ACR/ARHP Annual Meeting
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Background/Purpose: Health-related quality of life (HRQOL) is a key outcome in clinical care and research for children with JIA. Despite excellent clinical control and the…Abstract Number: 251 • 2013 ACR/ARHP Annual Meeting
Physical Activity Is Associated With Reduced Incident Disability: Evidence From The Osteoarthritis Initiative
Background/Purpose: Over 56 million people in the U.S. are classified as disabled. Physical activity is a low cost, broadly applicable approach to improve cardiovascular fitness,…Abstract Number: 2763 • 2013 ACR/ARHP Annual Meeting
Carotid Atherosclerosis As a Predictor Of Mortality In Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher mortality than do persons of the same age and sex without RA. This is due in part…Abstract Number: 2752 • 2013 ACR/ARHP Annual Meeting
Good, Moderate and Poor Outcome Trajectories Of Pain Severity In Early Symptomatic Knee Osteoarthritis; 5 Year Follow-Up Of Check study
Background/Purpose: Knee pain is often the first sign of knee OA (osteoarthritis) and it is known that its course can be very different between patients over…Abstract Number: 2328 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Background/Purpose: Tofacitinib is a novel, oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…Abstract Number: 1942 • 2013 ACR/ARHP Annual Meeting
Ultrasound Shows Tenosynovitis to be Frequently Present as Well As Sensitive to Change in RA Patients On Biologic Medication
Background/Purpose: Ultrasound (US) (grey scale (GS) and power Doppler (PD)) is a sensitive tool for examination of tenosynovitis in patients with rheumatoid arthritis (RA). The…Abstract Number: 1278 • 2012 ACR/ARHP Annual Meeting
Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Biologic therapies that block tumor necrosis factor-alpha (TNF) increase the risk of tuberculosis (TB), and screening for latent tuberculosis infection (LTBI) before their initiation…Abstract Number: 1282 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…Abstract Number: 1125 • 2012 ACR/ARHP Annual Meeting
Three Trajectories of Activity Limitations in Early Symptomatic Knee Osteoarthritis: A 5-Year Follow-up Study
Background/Purpose: Knee osteoarthritis (OA) is one of the leading causes of activity limitations among older adults. The course of activity limitations is highly variable; some…Abstract Number: 1126 • 2012 ACR/ARHP Annual Meeting
Comparison between Osteoartritis Initiative and CHECK study (Cohort Hip & Cohort Knee); Development of pain and function during 4 years follow-up
Background/Purpose: Pain and disability related to osteoarthritis (OA) may generally be considered to be chronic, but it is known that its course can be very…Abstract Number: 1110 • 2012 ACR/ARHP Annual Meeting
Radiologic Progression in Hand Osteoarthritis (OA) Over 2.6 Years – Data From the Sekoia Trial
Background/Purpose: Hand OA is a frequent polyarticular disease. Few is known with respect to its radiological progression over time, which in addition is difficult to…Abstract Number: 1032 • 2012 ACR/ARHP Annual Meeting
Medial Meniscal Root Tears and the Association with Meniscal Extrusion, Prevalent Cartilage Damage and Longitudinal Cartilage Loss: The MOST Study
Background/Purpose: The meniscal root is a ligamentous structure that anchors the posterior horn of the meniscus to the tibial plateau. The association of isolated meniscal…Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…Abstract Number: 653 • 2012 ACR/ARHP Annual Meeting
Longitudinal Analysis of Plasma Factors and Disease Activity Identifies Von Willebrand Factor As A Biomarker of Lupus Flare
Background/Purpose: Lupus, a chronic autoimmune disease, is characterized by a variable clinical course, with periods of active disease termed flares. The severity of flares can…